HK Stock Market Move | MICOT PHARMA-B (02335) rose over 3% as the Phase II clinical trial of MT200605 for the treatment of acute ischemic stroke reached its primary endpoint.

MICOT PHARMA-B (02335) rose over 3%, as of the time of writing, it has increased by 3.4%, trading at HK$30.4, with a transaction volume of HK$20.4952 million. In news, on August 3, MICOT PHARMA-B announced that the Phase II clinical trial of its independently developed candidate drug MT200605 for the treatment of Acute Ischemic Stroke (AIS) has achieved topline data. The data shows that this clinical trial has met its primary endpoint, with results demonstrating statistical significance and clinical relevance. Regarding safety, MT200605 has good safety and tolerability, with no severe adverse events (SAEs) related to the trial drug occurring throughout the study period, and treatment-emergent adverse events (TEAEs) of grade 3 or higher being balanced across all groups, with no new significant safety risks identified. In addition to being developed for the treatment of Acute Ischemic Stroke (AIS), MT200605 is also under development for the treatment of Huntingtons Disease (HD). MT200605 selectively activates the TrkB signaling pathway, exerting both neuroprotective and antioxidant effects to protect the structure and function of nervous tissue. Preclinical studies have shown that MT200605 has the potential to directly reduce the aggregation of mutant huntingtin protein (mHTT), thereby providing a treatment strategy with potential disease-modifying effects for HD. In March 2026, MT200605 received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the indication of HD.